A CAPITOL HILL LUNCH & BRIEFING:BIOTECHNOLOGY'S IMPACT ON DISEASES OF THE ELDERLY
FRIDAY, MAY 4, 2001 - 562 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, D.C. (May 3, 2001) - The Biotechnology Industry Organization (BIO) is sponsoring a luncheon and briefing on the impact of biotechnology on diseases of the elderly, Friday, May 4, 2001, in Room 562 of the Dirksen Senate Office Building beginning at 12:00 p.m.
Topics and Speakers include:
- Parexel overview - Charles Craig, Ernst & Young, Health Science Center for Industry Change
- Aging Diseases, Treatments and Research - Dr. Richard Hodes, director, National Institute on Aging
- Cancer Treatment and Future Therapies - Dr. Dawn Willis, director of scientific programs, American Cancer Society
- Update on Alzheimer's disease - Dr. Vincent Simmon, president and CEO, Cortex Pharmaceuticals
- Upcoming Treatments for Diabetes - Dr. Alain Baron, vice president of clinical research, Amylin Pharmaceuticals, and professor of medicine at Indiana University School of Medicine
BIO represents more than 950 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.
# # #